28
Participants
Start Date
January 31, 2014
Primary Completion Date
June 20, 2022
Study Completion Date
June 20, 2022
CT7, MAGE-A3, and WT1 mRNA-electroporated Langerhans cells ( LCs)
Patients receive CT7/MAGE-A3/WT1 mRNA-electroporated autologous Langerhans-type dendritic cells ID on days 12, 30, and 90 after autologous stem cell transplant. Patients on the vaccine arm of the study will receive a total of 3 vaccinations, comprising a primary immunization on day +12 after ASCT followed by two boosters at days +30 and +90. Vaccines will be dosed at 9x10\^6 LCs per vaccine x 3.
Standard of care
No vaccines
Memorial Sloan Kettering Cancer Center, New York
Memorial Sloan Kettering Cancer Center
OTHER